Research Progress of Small Molecule VEGFR/c-Met Inhibitors as Anticancer Agents (2016–Present)

Uses of cyclohexane-1,3-dione for the synthesis of 1,2,4-triazine derivatives as anti-proliferative agents and tyrosine kinases inhibitors

(2020) Nadia Y. Megally Abdo et al.   BIOORGANIC CHEMISTRY

c-Met as a new marker of cellular senescence

(2019) Maria Boichuck et al.   Aging-US

Design, synthesis and evaluation of sulfonylurea-containing 4-phenoxyquinolines as highly selective c-Met kinase inhibitors

(2019) Xiang Nan et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Design, synthesis and docking study of novel picolinamide derivatives as anticancer agents and VEGFR-2 inhibitors

(2019) Mohamed A. Zeidan et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Synthesis and anti-tumor activity of [1,4] dioxino [2,3-f] quinazoline derivatives as dual inhibitors of c-Met and VEGFR-2

(2019) Dengshuai Wei et al.   BIOORGANIC CHEMISTRY

Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors

(2019) Arpita Desai et al.   Future Oncology

Design, Synthesis, and Biological Evaluation of 4-Phenoxyquinoline Derivatives as Potent c-Met Kinase Inhibitor

(2019) Yifeng Yang et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Discovery of Dioxino[2,3-f]quinazoline derivative VEGFR-2 inhibitors exerting significant antipro-liferative activity in HUVECs and mice

(2019) Haoru Fan et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

2,7-naphthyridinone-based MET kinase inhibitors: A promising novel scaffold for antitumor drug development

(2019) Lin-Sheng Zhuo et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Triazolopyridazine derivatives: Synthesis, cytotoxic evaluation, c-Met kinase activity and molecular docking

(2019) Eman M. Ahmed et al.   BIOORGANIC CHEMISTRY

Design, synthesis and in vitro evaluation of 6-amide-2-aryl benzoxazole/benzimidazole derivatives against tumor cells by inhibiting VEGFR-2 kinase

(2019) Xu Yuan et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors

(2019) Heba T. Abdel-Mohsen et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Pyrazolo-benzothiazole hybrids: Synthesis, anticancer properties and evaluation of antiangiogenic activity using in vitro VEGFR-2 kinase and in vivo transgenic zebrafish model

(2019) Velma Ganga Reddy et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC

(2019) Eman M.E. Dokla et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Synthesis and biological evaluation of new MET inhibitors with 1,6-naphthyridinone scaffold

(2019) Ming-Shu Wang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

HER2 Confers Resistance to Foretinib Inhibition of MET-Amplified Esophageal Adenocarcinoma Cells

(2018) Alexei A. Goltsov et al.   ANNALS OF THORACIC SURGERY

Molecular docking simulation, synthesis and 3D pharmacophore studies of novel 2-substituted-5-nitro-benzimidazole derivatives as anticancer agents targeting VEGFR-2 and c-Met

(2018) Heba A. Ibrahim et al.   BIOORGANIC CHEMISTRY

Molecular dynamics guided development of indole based dual inhibitors of EGFR (T790M) and c-MET

(2018) Pankaj Kumar Singh et al.   BIOORGANIC CHEMISTRY

Design, synthesis and biological evaluation of pyrimidine-based derivatives as VEGFR-2 tyrosine kinase inhibitors

(2018) Wuji Sun et al.   BIOORGANIC CHEMISTRY

Vascular endothelial growth factor signaling in development and disease

(2018) Sinem Karaman et al.   DEVELOPMENT

Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study

(2018) Ana M. Molina et al.   EUROPEAN JOURNAL OF CANCER

Synthesis and bioevaluation and doking study of 1 H -pyrrolo[2,3- b ]pyridine derivatives bearing aromatic hydrazone moiety as c-Met inhibitors

(2018) Wenhui Wang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Dual or multi-targeting inhibitors: The next generation anticancer agents

(2018) Nulgumnalli Manjunathaiah Raghavendra et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Design, synthesis, biological evaluation and molecular modeling of novel 1 H -pyrazolo[3,4-d]pyrimidine derivatives as BRAF V600E and VEGFR-2 dual inhibitors

(2018) Yuanyuan Wang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Design, synthesis and molecular modeling study for some new 2-substituted benzimidazoles as dual inhibitors for VEGFR-2 and c-Met

(2018) Heba A Ibrahim et al.   Future Medicinal Chemistry

Structure activity relationships of chrysoeriol and analogs as dual c‑Met and VEGFR2 tyrosine kinase inhibitors

(2018) Shuang Lai et al.   ONCOLOGY REPORTS

Exploration of novel pyrrolo[2,1-f][1,2,4]triazine derivatives with improved anticancer efficacy as dual inhibitors of c-Met/VEGFR-2

(2018) Wei Shi et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Synthesis and biological evaluation of novel 6,11-dihydro-5 H -benzo[e]pyrimido- [5,4- b ][1,4]diazepine derivatives as potential c-Met inhibitors

(2017) Daowei Huang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Identification of 3-substituted-6-(1-(1 H -[1,2,3]triazolo[4,5- b ]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization

(2017) Fei Zhao et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors

(2017) Lin Xiao Wang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of novel anti-angiogenesis agents. Part 7: Multitarget inhibitors of VEGFR-2, TIE-2 and EphB4

(2017) Chuansheng Li et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016)

(2017) Fan-Wei Peng et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Design, Synthesis, and Biological Evaluation of the First c-Met/HDAC Inhibitors Based on Pyridazinone Derivatives

(2017) Dong Lu et al.   ACS Medicinal Chemistry Letters

Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment

(2017) Natalie Rothenberger et al.   Cancers

The Therapeutic Targeting of HGF/c-Met Signaling in Hepatocellular Carcinoma: Alternative Approaches

(2017) Chi-Tan Hu et al.   Cancers

Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors

(2016) Xin Zhai et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Design, synthesis and biological evaluation of 4-aminopyrimidine-5-cabaldehyde oximes as dual inhibitors of c-Met and VEGFR-2

(2016) Hao Qiang et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Discovery of novel pyrrolo[2,3-b]pyridine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors

(2016) Qidong Tang et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs

(2016) Jin Zhang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing 1,2,4-triazolone moiety as c-Met kinase inhibitors

(2016) Ju Liu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Sustained inhibition of cMET-VEGFR2 signaling using liposome-mediated delivery increases efficacy and reduces toxicity in kidney cancer

(2016) Ashish A. Kulkarni et al.   Nanomedicine-Nanotechnology Biology and Medicine

Ten years of anti-vascular endothelial growth factor therapy

(2016) Napoleone Ferrara et al.   NATURE REVIEWS DRUG DISCOVERY

Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents

(2016) Beverly L. Falcon et al.   PHARMACOLOGY & THERAPEUTICS

Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors

(2015) Dieter Dorsch et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Discovery of quinazolin-4-amines bearing benzimidazole fragments as dual inhibitors of c-Met and VEGFR-2

(2014) Lei Shi et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Discovery of novel type II c-Met inhibitors based on BMS-777607

(2014) Wei Zhang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies

(2014) Mohammad Hojjat-Farsangi   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Discovery of Anilinopyrimidines as Dual Inhibitors of c-Met and VEGFR-2: Synthesis, SAR, and Cellular Activity

(2014) Zhengsheng Zhan et al.   ACS Medicinal Chemistry Letters

RON confers lapatinib resistance in HER2-positive breast cancer cells

(2013) Quanren Wang et al.   CANCER LETTERS

Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress

(2013) J. Jean Cui   JOURNAL OF MEDICINAL CHEMISTRY

Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment

(2013) Y Kwon et al.   ONCOGENE

Discovery of Plumericin as a novel potent NF-κB inhibitor from Himatanthus sucuuba

(2013) N Fakhrudin et al.   PLANTA MEDICA

Associations of VEGF/VEGF-Receptor and HGF/c-Met Promoter Polymorphisms With Progression/Regression of Retinopathy of Prematurity

(2012) Mahmut Kaya et al.   CURRENT EYE RESEARCH

Higher Levels of c-Met Expression and Phosphorylation Identify Cell Lines With Increased Sensitivity to AMG-458, a Novel Selective c-Met Inhibitor With Radiosensitizing Effects

(2012) Bo Li et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors

(2011) J.- C. Soria et al.   ANNALS OF ONCOLOGY

Foretinib (GSK1363089), an Orally Available Multikinase Inhibitor of c-Met and VEGFR-2, Blocks Proliferation, Induces Anoikis, and Impairs Ovarian Cancer Metastasis

(2011) M. Zillhardt et al.   CLINICAL CANCER RESEARCH

Recent Advances in Antiangiogenic Agents with VEGFR as Target

(2011) J. Zhang et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY

Cell Signaling by Receptor Tyrosine Kinases

(2010) Mark A. Lemmon et al.   CELL

106 Preclinical studies and characterization of BMS-794833, a small molecule inhibitor of Met and VEGFR-2 kinases

(2010) J. Fargnoli et al.   EJC SUPPLEMENTS

Recent Progress of Small Molecular VEGFR Inhibitors as Anticancer Agents

(2010) D. Xu et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY